2023 NHCA Annual Conference

Co-Author: Michael Hoffer

Despite hearing protection device (HPD) requirements within occupational hearing loss prevention programs, the prevalence of noise-induced hearing loss (NIHL) remains stubbornly high. The continued problem of NIHL, combined with advances in understanding of cell death in the inner ear, has stimulated the development of medicines that may one day prevent acquired hearing loss such as NIHL, as well as hearing loss associated with ototoxic prescription medicines. In addition, efforts to develop gene and small molecule therapies that can re-activate developmental sequences in the inner ear and restore auditory function are robust. The combination of prevention and restoration therapies could positively impact individual patients and ameliorate this important public health issue. There are no current medications approved by the U.S. Food and Drug Administration at this time, but development of therapeutics for diverse hearing and balance indications is a highly active research space. This workshop will provide a basic introduction to the science of auditory medicines, explaining why they provide benefits in animals; summarize the clinical testing process and the pathway for investigational medicines; briefly review ongoing and completed clinical trials; and share specific messaging for patients regarding possible treatment options for acute NIHL as well over-the-counter supplements.